Levin Capital Strategies, L.P. Denali Therapeutics Inc. Transaction History

Levin Capital Strategies, L.P.

  • $1.03 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 06, 2024
BUY
$16.2 - $23.18 $162,000 - $231,800
10,000 Added 71.43%
24,000 $515,000
Q3 2023

Oct 31, 2023
BUY
$20.63 - $30.17 $134,095 - $196,105
6,500 Added 86.67%
14,000 $288,000
Q2 2023

Jul 31, 2023
BUY
$23.37 - $32.96 $175,275 - $247,200
7,500 New
7,500 $221,000
Q3 2022

Nov 08, 2022
BUY
$25.97 - $38.53 $181,790 - $269,710
7,000 Added 280.0%
9,500 $292,000
Q2 2022

Aug 15, 2022
BUY
$20.88 - $35.19 $52,200 - $87,975
2,500 New
2,500 $74,000

Others Institutions Holding DNLI

# of Institutions
227
Shares Held
119M
Call Options Held
60.6K
Put Options Held
48.4K
View Full List

About Denali Therapeutics Inc.

DNLI Quotes by TradingView
  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track Levin Capital Strategies, L.P. Portfolio

Follow Levin Capital Strategies, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Levin Capital Strategies, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Levin Capital Strategies, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email